{"id":119,"date":"2019-01-08T10:47:13","date_gmt":"2019-01-08T10:47:13","guid":{"rendered":"https:\/\/medphys.royalsurrey.nhs.uk\/prospects\/?page_id=119"},"modified":"2019-01-18T11:43:40","modified_gmt":"2019-01-18T11:43:40","slug":"trial-endpoints","status":"publish","type":"page","link":"https:\/\/medphys.royalsurrey.nhs.uk\/prospects\/about-the-prospects-trial\/trial-endpoints\/","title":{"rendered":"TRIAL ENDPOINTS"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Primary end-point.<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>Invasive cancer detection rates.<\/li><li>Interval cancer rates.<\/li><li>Size and\u00a0lymph node\u00a0status of grade 2 and 3 invasive cancers.<\/li><li>Cost-effectiveness \u00a0of screening with\u00a0DBT\u00a0+\u00a02DDM\u00a0or S2D vs screening with\u00a02DDM. <\/li><\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>Secondary end-point.<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\"><li>Measurement of invasive cancer detection rates using\u00a0DBT\u00a0+ S2D vs\u00a02DDM.<\/li><li>Recall rates.<\/li><li>Benign biopsy rates at assessment.<\/li><li>Benign\u00a0surgical biopsy\u00a0rates.<\/li><li> Measurement of cancer detection rates, recall rates in subgroups of women in intervention and control groups defined by breast density, type of screen, age group. <\/li><li>Development of a method for measurement of reader performance. <\/li><li>Results of retrospective reader studies to compare different screening strategies including\u00a02DDM\u00a0+ synthetic 2D,\u00a0DBT\u00a0alone,\u00a02DDM\u00a0+ limited <g class=\"gr_ gr_11 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling\" id=\"11\" data-gr-id=\"11\">tomo<\/g> views. <\/li><li> Measurement of trial participant experience of\u00a0DBT\u00a0+\u00a02DDM\u00a0vs\u00a02DDM. <\/li><\/ol>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"Primary end-point. Invasive cancer detection rates. Interval cancer rates. Size and\u00a0lymph node\u00a0status of grade 2 and 3 invasive cancers. Cost-effectiveness \u00a0of screening with\u00a0DBT\u00a0+\u00a02DDM\u00a0or S2D vs screening with\u00a02DDM. Secondary end-point. Measurement of invasive cancer detection rates using\u00a0DBT\u00a0+ S2D vs\u00a02DDM. Recall rates. Benign biopsy rates at assessment. Benign\u00a0surgical biopsy\u00a0rates. Measurement of cancer detection rates, recall rates in&#8230; <a class=\"view-article\" href=\"https:\/\/medphys.royalsurrey.nhs.uk\/prospects\/about-the-prospects-trial\/trial-endpoints\/\">View Article<\/a>","protected":false},"author":4,"featured_media":0,"parent":197,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-119","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/medphys.royalsurrey.nhs.uk\/prospects\/wp-json\/wp\/v2\/pages\/119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medphys.royalsurrey.nhs.uk\/prospects\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/medphys.royalsurrey.nhs.uk\/prospects\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/medphys.royalsurrey.nhs.uk\/prospects\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medphys.royalsurrey.nhs.uk\/prospects\/wp-json\/wp\/v2\/comments?post=119"}],"version-history":[{"count":5,"href":"https:\/\/medphys.royalsurrey.nhs.uk\/prospects\/wp-json\/wp\/v2\/pages\/119\/revisions"}],"predecessor-version":[{"id":481,"href":"https:\/\/medphys.royalsurrey.nhs.uk\/prospects\/wp-json\/wp\/v2\/pages\/119\/revisions\/481"}],"up":[{"embeddable":true,"href":"https:\/\/medphys.royalsurrey.nhs.uk\/prospects\/wp-json\/wp\/v2\/pages\/197"}],"wp:attachment":[{"href":"https:\/\/medphys.royalsurrey.nhs.uk\/prospects\/wp-json\/wp\/v2\/media?parent=119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}